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Abstract
The fibroblast growth factor (FGF)-FGF receptor (FGFR) signaling system plays critical roles in a variety of normal
developmental and physiological processes. It is also well documented that dysregulation of FGF-FGFR signaling may have
important roles in tumor development and progression. The FGFR4–FGF19 signaling axis has been implicated in the
development of hepatocellular carcinomas (HCCs) in mice, and potentially in humans. In this study, we demonstrate that
FGFR4 is required for hepatocarcinogenesis; the progeny of FGF19 transgenic mice, which have previously been shown to
develop HCCs, bred with FGFR4 knockout mice fail to develop liver tumors. To further test the importance of FGFR4 in HCC,
we developed a blocking anti-FGFR4 monoclonal antibody (LD1). LD1 inhibited: 1) FGF1 and FGF19 binding to FGFR4, 2)
FGFR4–mediated signaling, colony formation, and proliferation in vitro, and 3) tumor growth in a preclinical model of liver
cancer in vivo. Finally, we show that FGFR4 expression is elevated in several types of cancer, including liver cancer, as
compared to normal tissues. These findings suggest a modulatory role for FGFR4 in the development and progression of
hepatocellular carcinoma and that FGFR4 may be an important and novel therapeutic target in treating this disease.
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Introduction
Fibroblast growth factors (FGFs) comprise a family of 22
structurally related polypeptides with diverse biological activities
[1]. Most of these signaling molecules function by binding to and
activating members of the FGF receptor (FGFR) family of receptor
tyrosine kinases, of which there are four members designated
FGFR1–4 [2]. These receptor-ligand interactions result in
receptor dimerization and autophosphorylation, formation of
complexes with membrane-associated and cytosolic accessory
proteins, and initiation of multiple signaling cascades [3]. The
FGFR-FGF signaling system plays important roles in development
and tissue repair by regulating cellular functions/processes such as
growth, differentiation, migration, morphogenesis, and angiogen-
esis. Not surprisingly, dysregulation of this signaling axis has also
been shown to play significant roles in tumor development and
progression.
Alterations in FGFRs (i.e. overexpression, mutation, transloca-
tion, and truncation) are associated with a number of human
cancers, including myeloma, breast, stomach, colon, bladder,
pancreatic, and hepatocellular carcinomas
[4,5,6,7,8,9,10,11,12,13]. Hepatocellular carcinoma (HCC) is
one of the leading global causes of cancer related deaths, resulting
in over half a million fatalities per year [14]. While the role of
FGFR4 in cancer remains to be fully elucidated, several findings
suggest that this receptor may be an important player in HCC
development and/or progression. FGFR4 is the predominant
FGFR isoform present in human hepatocytes [15]. We have also
previously reported that liver tissue has the highest transcript levels
of FGFR4 [16]. In addition to FGFR4 being overexpressed in
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HCC patient samples [17]. Notably, a highly frequent G388R
single nucleotide polymorphism in FGFR4 (associated with
reduced survival for head and neck carcinoma, as well as a more
aggressive phenotype for colon, soft tissue, prostate, and breast
carcinomas) was identified [17]. Furthermore, it has been
previously demonstrated that ectopic expression of FGF19 (i.e.
FGFR4-specific ligand) in mice promotes hepatocyte proliferation,
hepatocellular dysplasia, and neoplasia [18]. We and others have
also recently demonstrated that Klotho b (KLB) is required for the
liver-specific activities of FGF19 and that KLB is most highly
expressed in liver, along with FGFR4, further supporting the
premise that the liver uniquely possesses the necessary machinery
required for the activity of this signaling system [16,19]. Finally, it
has been reported that FGFR4-FGF19 can crosstalk with b-
catenin signaling and that inactivation of either FGFR4 or FGF19
reduces tumorigenesis [20].
To test the importance of FGFR4 in hepatocellular carcinoma,
we evaluated the effect of its ablation in a genetically engineered
mouse model of HCC and assessed the effects of therapeutic
FGFR4 neutralization in relevant mouse tumor models. We
demonstrate here that FGFR4 is required for FGF19-mediated
liver tumorigenesis in vivo and show that treatment with an
FGFR4 neutralizing antibody inhibited FGFR4-mediated signal-
ing, proliferation, and colony formation in cell-based assays and
tumor growth in preclinical models of HCC in vivo. We also show
that FGFR4 expression is elevated in several types of cancer,
including liver cancer, as compared to normal tissues. These
findings provide evidence for a modulatory role of FGFR4 in
HCC development and progression and suggest that FGFR4 may
be an important and novel therapeutic target in treating this
disease.
Results
FGFR4 is Required for Hepatocarcinogenesis in FGF19
Transgenic Mice
The exogenous expression of FGF19 in transgenic mice was
previously shown to cause HCC by the age of 10 months [18]. To
assess whether FGFR4 is involved in this FGF19-mediated
tumorigenesis we bred the FGF19 transgenic (FGF19-TG) mice
with FGFR4 knockout (FGFR4-KO) mice or FGFR4 wild type
(FGFR4-WT) mice. The mice were necropsied at various time
points and liver carcinogenesis was assessed by performing gross
and pathological histology examinations and by measuring
preneoplastic hepatocellular proliferation (i.e. BrdU incorpora-
tion). The development of HCC in FGF19-TG:FGFR4-WT mice
was as previously described [18]. Contrary to the FGF19-
TG:FGFR4-WT mice, the FGF19-TG:FGFR4-KO mice did not
develop gross or histological evidence of hepatocellular neoplasia
at any time during this experiment (Fig. 1A). Also, preneoplastic
hepatocellular proliferation was significantly elevated in FGF19-
TG mice that had the FGFR4-WT genotype, but was not evident
in the FGF19-TG:FGFR4-KO littermates (Fig. 1B). Consistent
with the previously reported higher frequency and severity of
tumor development in female FGF19-TG mice [18], the BrdU
incorporation was increased in FGF19-TG:FGFR4-WT females
as compared to the corresponding males (compare left and right
panels of Fig. 1B). We also evaluated the effect of diethylnitro-
samine (DEN), a potent liver carcinogen, on the development of
HCC in FGF19-TG mice. The administration of DEN accelerated
the development of HCC in FGF19-TG:FGFR4-WT mice. The
entire range of preneoplastic and neoplastic lesions – altered
(basophilic) hepatic foci, pericentral hepatocyte dysplasia, well
differentiated hepatocellular neoplasms, and aggressive hepatocel-
lular carcinomas – was seen in livers from all DEN-treated FGF19-
TG:FGFR4-WT animals by 4 months of age (Fig. 1C) as
compared to 10 months of age for the non-DEN-treated
FGF19-TG:FGFR4-WT mice. The cardinal morphologic charac-
teristic of livers from almost all FGF19-TG:FGFR4-WT mice at
all time points was grossly evident nodules of HCC on multiple
lobes (Fig. 1D). The tumor burden was evaluated by measuring
liver weight. The relative liver weights increased progressively at
all time points in FGF19-TG:FGFR4-WT mice treated with DEN
(Fig. 1E). Interestingly, the increase in liver weight was more
pronounced in females (2.7-fold at 6 months) than in males (1.8-
fold at 6 months) (compare left and right panels of Fig. 1E). It
should be noted that none of the males survived past 6 months of
age (Fig. 1E). The hepatocarcinogenesis observed in the FGF19-
TG:FGFR4-WT mice treated with DEN was abolished by the
removal of FGFR4 expression in the FGFR4-KO mice. Accord-
ingly, the relative liver weight of FGF19-TG:FGFR4-KO mice
remained constant during adulthood (Fig. 1F). These results
suggest that FGFR4 expression is required for FGF19-promoted
hepatocarcinogenesis in mice.
Generation of an Anti-FGFR4 Neutralizing Monoclonal
Antibody
To evaluate whether targeting FGFR4 could have a therapeutic
impact in HCC we generated an FGFR4-specific monoclonal
antibody by immunizing FGFR4-KO mice with recombinant
mouse and human FGFR4. One of the resulting clones, designated
as LD1, was selected for the specificity of its binding to mouse,
cynomolgus monkey, and human FGFR4 (Figs. 2A and S1). This
antibody did not bind to mouse or human FGFR1, FGFR2, or
FGFR3 (Figs. 2A and S1). Surface plasmon resonance analysis
revealed that LD1 bound to mouse, cynomolgus monkey, and
human FGFR4 with comparable affinity (Fig. 2B). We used flow
cytometry to evaluate whether LD1 bound to FGFR4 present at
the cell surface. The specific binding of LD1 to HEK293 cells
stably transfected with human FGFR4 was proportional to the
concentration of antibody added (Fig. 2C). There was no binding
of LD1 to control HEK293 cells stably transfected with an empty
vector (Fig. S1). Together these data demonstrate that LD1 binds
specifically to mouse, cynomolgus monkey, and human FGFR4
and also recognizes the human receptor when expressed at the cell
surface.
To map the FGFR4 epitope for LD1, we compared the amino
acid sequences of mouse and human FGFR1, FGFR2, FGFR3,
and FGFR4. Eight amino acids were selected based on their
similarity between the FGFR4 orthologs and their dissimilarity in
the FGFR1-3 orthologs. These amino acids in FGFR4 were
substituted with the amino acids present at the equivalent positions
in FGFR3 to generate eight different mutant constructs of human
FGFR4. These constructs were expressed and evaluated for LD1
binding using a solid phase binding assay. LD1 bound equally well
to wild type FGFR4 and most of the mutant constructs; G165A
was the only FGFR4 mutant for which LD1 binding was
compromised (Fig. 2D). LD1 did not bind to the negative control
wild type FGFR3 (Fig. 2D). We also tested the binding of LD1 to
the mutant constructs using immunoblot analysis. All previously
described protein constructs were reduced, denatured, electro-
phoresed, and electro-transferred to nitrocellulose. The nitrocel-
lulose membrane was sequentially incubated with LD1, an anti-
FGFR4 antibody recognizing a different epitope (8G11), or an
anti-FLAG antibody. The anti-FLAG antibody and 8G11
detected wild type FGFR4 and all FGFR4 mutant constructs
while LD1 detected all constructs equally well with the exception
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any of the antibodies in the control lanes (Fig. 2E). We generated a
three-dimensional model of an FGFR4 dimer bound to two
molecules of FGF19 to visualize the location of G165 (Fig. 2F).
G165 is localized in the center of the FGFR4-FGF19 complex at
the point of contact between the two FGFR4 units. Together these
Figure 1. FGFR4 is required for FGF19-mediated liver tumorigenesis. A, Multiple, large, raised tumors (arrows) protruding from the hepatic
surface of a 10-month-old FGF19-TG:FGFR4-WT mouse (left panel). Liver from a 10-month-old FGF19-TG:FGFR4-KO mouse (right panel). B, BrdU
incorporation in female (left panel) and male (right panel) FGF19-TG or wild type mice bred with FGFR4-KO or FGFR4-WT mice. C, Prevalence of liver
tumors in male and female FGF19-TG mice treated with DEN as determined by gross and histological examinations. D, Multiple, large, raised tumors
(arrows) on the surface of the liver of a 4-month-old FGF19-TG:FGFR4-WT mouse treated with DEN. E, Liver weights from FGF19-TG or wild type
female (left panel) and male (right panel) mice treated with DEN. The asterisk (*) indicates that the weight of the liver could not be measured from the
7-month time point for male FGF19-TG mice treated with DEN because none survived past 6 months of age. F, Liver weights of FGF19-TG or wild type
female (left panel) and male (right panel) FGFR4-KO mice treated with DEN.
doi:10.1371/journal.pone.0036713.g001
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human FGFR4. The binding of LD1 to reduced and denatured
FGFR4 also suggests that the epitope does not depend on ternary
confirmation.
Next we tested whether LD1 could block the binding of FGF1
and FGF19 to FGFR4 using a solid phase receptor-binding
assay. The LD1 inhibition of FGF binding was dose-dependent
and reached an IC50 of 0.09360.006 nM for FGF1 and
0.10260.003 nM for FGF19 (Fig. 3A). To evaluate whether
LD1 could inhibit the functions of FGFR4 expressed at the cell
surface we first utilized a BaF3 murine pro-B cell line stably
transfected with a chimeric construct that encodes for the
extracellular domain of FGFR4 and the intracellular domain of
FGFR1 (BaF3/FGFR4/R1). The wild type BaF3 cell line is an
interleukin-3 (IL-3)-dependent cell line that does not express any
FGFRs. BaF3 cells transfected with FGFR expression constructs
proliferate in the absence of IL-3 when stimulated with FGF and
heparin [21]. The transfection of this construct allowed us to
substitute FGFs for IL-3 to support the growth of the BaF3 cells.
In the presence of 5 nM FGF1, LD1 inhibited the proliferation
of BaF3/FGFR4/R1 cells with an IC50 of 17.465.4 nM
(Fig. 3B).
We also used the L6 rat skeletal muscle cell line stably
transfected with a vector expressing FGFR4 (L6/FGFR4) to
evaluate the effect of LD1 on FGF signaling. The addition of
FGF1 and heparin to the L6/FGFR4 cell cultures activated the
FGFR pathway as demonstrated by the phosphorylation of FGFR
substrate 2 (FRS2) and extracellular signal-regulated kinase 1/2
(ERK1/2) while LD1 inhibited the ligand-induced phosphoryla-
tion of these secondary messengers in a dose-dependent manner
(Fig. 3C). Interestingly, the addition of LD1 also triggered an
increase in total FRS2 content in these cells (Fig. 3C).
Figure 2. LD1 binds to FGFR4. A, LD1 binds to human (h), mouse (m), and cynomolgus monkey (c) FGFR4, but does not bind to hFGFR1, hFGFR2,
or hFGFR3. The binding of LD1 to immobilized FGFR-Fc chimeric proteins was determined by solid phase binding assay. B, Affinity of LD1 binding to
mouse, cynomolgus monkey, and human FGFR4 as determined by surface plasmon resonance. C, Binding of LD1 to hFGFR4 expressed at the cell
surface of stably transfected HEK293 cells as measured by FACS (RFU = Relative Fluorescence Unit). D, The binding of LD1 to immobilized hFGFR4-
Flag chimeric proteins bearing point mutations as measured by a solid phase binding assay. E, The binding of LD1 to hFGFR4-Flag chimeric proteins
bearing point mutations as evaluated by Western blot. Mutated proteins were electrophoresed and sequentially immunoblotted using LD1, an anti-
FGFR4 (8G11), and an anti-Flag antibody. F, Dimer model illustrating the position of G165 (blue) on FGFR4 (red and yellow) bound to FGF19 (green).
doi:10.1371/journal.pone.0036713.g002
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confirmed the expression of FGFR4 at the cell surface of a subset
of HCC cell lines. LD1 bound most highly to PLC/PRF/5 cells
and bound to a lesser extent to HUH7 and JHH5 cells (Fig. 3D).
The binding of a control antibody to the surface of these cells was
negligible (Fig. 3D). Furthermore, the binding of LD1 and the
control antibody to the surface of BaF3 cells, which were used as a
negative control because they do not express FGFR4, was also
negligible (Fig. 3D).
LD1 Inhibits FGFR4 Functions in Liver Cancer Cell Lines
The inhibitory activity of LD1 was characterized using liver
cancer cell lines with various levels of endogenous FGFR (i.e.
FGFR1-4) expression (Fig. S2). In HEP3B cells, the addition of
FGF19 triggered the phosphorylation of FRS2 and ERK1/2 while
LD1 inhibited the FGF19-stimulated phosphorylation of FRS2
(Fig. 4A), similar to its effect on L6/FGFR4 cells. LD1, however,
did not appreciably alter the phosphorylation of ERK1/2 (Fig. 4A).
The expression of cholesterol 7a-hydroxylase (CYP7A1) and c-
Fos (FOS) genes is modulated by FGF19 in liver cell lines [16,22].
We tested whether LD1 could inhibit this FGF19-mediated gene
modulation. In HEP3B cells, the addition of FGF19 reduced the
expression of CYP7A1 by 81% (Fig. 4B). The addition of LD1
restored 67% of the basal expression of CYP7A1 (Fig. 4B). In the
absence of added FGF19, LD1 increased CYP7A1 expression by 2-
fold (Fig. 4B). Although the addition of FGF19 did not affect the
expression of CYP7A1 in HUH7 cells, the addition of LD1 had a
similar effect as in HEP3B cells, increasing the expression of this
gene by 2.9- and 3.5-fold in the presence or the absence of FGF19,
respectively (Fig. S3). The addition of a negative control antibody
had no effect on the expression of CYP7A1 in either HEP3B or
HUH7 cells (Figs. 4B and S3, respectively). Interestingly, the
addition of LD1 leads to the upregulation of CYP7A1 expression in
the absence of exogenously added FGFR4 ligand in both HEP3B
and HUH7 cells. This indicates that LD1 inhibits the FGFR4
basal activity possibly maintained by an FGFR4 ligand autocrine/
paracrine loop.
To further evaluate the effect of LD1 on the basal activity of
FGFR4 we measured the expression of FOS in the absence of
exogenously added FGFR4 ligand. The activation of the FGFR4
pathway was previously shown to increase FOS expression [16].
The addition of LD1 decreased the basal expression of FOS by
50% in JHH5, JHH7, and HUH7 cell lines and by 75% in the
PLC/PRF/5 cell line; addition of a control antibody had no effect
on basal FOS expression (Fig. 4C). These results demonstrate the
ability of LD1 to inhibit the basal activity of FGFR4.
LD1 Inhibits Colony Formation
We first measured colony formation by JHH5 cells stably
transfected with a doxycycline-inducible FGFR4-specific shRNA
or a control shRNA. Although there was no difference in the
ability of JHH5 cells transfected with the control construct to form
colonies in the absence or presence of doxycycline, the addition of
doxycycline to the JHH5 cells transfected with the FGFR4 shRNA
construct inhibited colony formation by 76% as compared to cells
in the absence of doxycycline (Fig. 4D). This result suggests that
FGFR4 is involved in the colony formation of liver cancer cell
lines.
Figure 3. LD1 inhibits FGFR4 activities. A, LD1 inhibits FGFR4 binding to FGF1 and FGF19 as determined by solid phase binding assay. B, LD1
inhibits FGF1-stimulated proliferation of BaF3 cells stably expressing FGFR4/R1. C, LD1 inhibits FGFR4 signaling in L6 cells stably expressing FGFR4. D,
Cell surface expression of FGFR4 protein in a subset of liver tumor cell lines as determined by FACS analysis using LD1.
doi:10.1371/journal.pone.0036713.g003
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a panel of liver cancer cell lines. The addition of LD1 to cultures of
JHH5, HUH7, and PLC/PRF/5 cells caused a dose-dependent
reduction in colony formation, reaching a maximum inhibition of
26%, 50%, and 82%, respectively (Fig. 4E). Representative
examples of PLC/PRF/5 and HUH7 cell cultures are shown in
Fig. 4F. The addition of a control antibody did not affect colony
formation (Figs. 4E and 4F). These results indicate that LD1
inhibits FGFR4-mediated colony formation in liver cancer cell
lines.
LD1 Inhibits FGFR4 in vivo Activity
We evaluated the in vivo efficacy of LD1 by measuring the
FGF19-triggered FOS induction in the livers of mice injected
with LD1 or a control antibody. We chose to monitor the FOS
response to FGF19 because FOS induction in the liver is sensitive
to FGF19 stimulation [16]. FOS expression was 53-fold higher in
the livers of mice treated with FGF19 compared with livers of
mice treated with phosphate buffered saline (PBS) (Fig. 5A). The
administration of LD1 48 hours prior to the injection of FGF19
reduced the FOS induction by 3.5-fold (Fig. 5A). LD1 also
Figure 4. LD1 inhibits FGFR4 biological activities in liver cancer cell lines. A, LD1 inhibits FGFR4 signaling in HEP3B cells as evaluated by
Western blot. B, LD1 inhibits the FGFR4-regulated CYP7A1 repression in HEP3B cells. CYP7A1 levels are represented as fold expression relative to the
level in untreated cells. C, LD1 inhibits FGFR4-regulated FOS expression in a panel of liver cancer cell lines. The results are represented as fold
expression relative to the FOS level in untreated cells. D, Inhibition of colony formation by repression of FGFR4 expression in JHH5 cells stably
transfected with an FGFR4 shRNA doxycycline-inducible vector. E, Enumeration of LD1-inhibited liver cancer cell line colony formation. The values are
represented as percent of the number of colonies enumerated in the absence of added LD1. F, LD1 inhibits HCC cell line colony formation.
doi:10.1371/journal.pone.0036713.g004
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(Fig. 5A). The injection of a control antibody did not alter the
basal or the FGF19-stimulated expression of FOS compared to
the non-treated mice (Fig. 5A). These data demonstrate the in
vivo efficacy of LD1 at inhibiting the basal and the FGF19-
stimulated FGFR4 activity.
LD1 inhibits tumor growth in vivo
To examine the in vivo efficacy of LD1 at inhibiting tumor
growth we first utilized the HUH7 liver cancer cell line xenograft
model. Mice bearing established tumors (approximately 150 mm
3)
were dosed weekly with 30 mg/kg LD1, 30 mg/kg control
antibody, or PBS. After 13 days, the HUH7 tumors of mice
treated with either PBS or control antibody grew to an average
size of 720 mm
3 (Fig. 5B). However, the HUH7 tumors of mice
treated with LD1 grew to an average size of 28 mm
3, a 96%
inhibition of tumor growth as compared to control antibody or
PBS (Fig. 5B). In a repeat experiment, the administration of
30 mg/kg of LD1 twice per week caused complete tumor growth
inhibition (Fig. S4). At necropsy, the tumors were excised and the
effect of LD1 on the expression of FGFR4 and FGFR4-regulated
genes was evaluated. The administration of LD1 did not affect
FGFR4 expression in HUH7 xenograft tumors (Fig. 5C). However,
LD1 increased the expression of CYP7A1 by 3-fold compared to
the level of expression of CYP7A1 measured in the tumors of PBS-
treated mice (Fig. 5C). LD1 also reduced the expression of FOS
Figure 5. In vivo efficacy of LD1. A, LD1 inhibits FGF19-regulated FOS expression in mouse liver. The results are represented as fold expression
relative to FOS levels in the livers of non-treated mice. B, LD1 (30 mg/kg; once weekly) inhibits HUH7 xenograft tumor growth in vivo. C, Effects of LD1
on the mRNA expression of FGFR4, CYP7A1, FOS, and EGR1 in HUH7 xenograft tumors from Fig. 5B. D, Multiple, large, raised tumors (arrows)
protruding from the hepatic surface of a DEN-accelerated FGF19-TG:FGFR4-WT mouse treated with a control antibody (upper panel). Liver of DEN-
accelerated FGF19-TG:FGFR4-WT mouse treated with LD1 (lower panel). E, Liver weights of DEN–accelerated FGF19-TG:FGFR4-WT mice treated with
control antibody, LD1, or 1A6 (anti-FGF19 antibody).
doi:10.1371/journal.pone.0036713.g005
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treated mice (Fig. 5C).
To further evaluate the in vivo efficacy of LD1 we used the
FGF19-TG mouse model. FGF19-TG mice were treated with
DEN at 15 days of age to accelerate tumorigenesis and then
randomly grouped into 3 cohorts at 4 weeks of age. One group
received a control antibody and the other two groups received
either LD1 or an anti-FGF19 antibody (1A6) on a weekly basis.
1A6 was previously shown to prevent tumor formation in FGF19-
TG mice [23]. After 6 months, the mice were necropsied and the
livers were excised for analyses. The livers of mice treated with the
control antibody had grossly evident large nodules on multiple
lobes (Fig. 5D). However, the livers of mice treated with LD1
(Fig. 5D) or 1A6 (data not shown) had no evidence of neoplasia.
We also measured liver weights to evaluate tumor burden because
this parameter was previously shown to strongly correlate with
percent tumor volume in the FGF19-TG model [18,23]. The
weight of the livers from mice treated with LD1 or 1A6 was
significantly (p=0.035 and p=0.052, respectively) lower than the
weight of the livers from mice treated with control antibody
(Fig. 5E). The difference in liver weight between mice treated with
LD1 and the mice treated with 1A6 was not significant (p=0.439)
(Fig. 5E). Together these data clearly demonstrate the in vivo
efficacy of LD1 at inhibiting hepatocellular carcinoma in
preclinical models.
FGFR4 Expression is Altered in Cancer
We evaluated FGFR4 expression in a variety of human normal
and cancerous tissues by analyzing the BioExpress database (Gene
Logic, Inc., Gaithersburg, MD, USA). FGFR4 expression is highly
variable in most types of cancer. Compared to normal tissues,
FGFR4 expression was elevated in liver, colorectal, stomach,
esophageal, and testicular cancers, but diminished in kidney, lung,
lymphoid, and small intestine cancers (Fig. 6A). Using immuno-
histochemistry we localized FGFR4 in a panel of lung, breast,
pancreas, and ovarian adenocarcinomas, lung squamous cell
carcinoma, hepatocellular carcinoma, thyroid carcinoma, and
normal lung, pancreas, and thyroid samples. The detection of
FGFR4 gave rise to membranous and cytoplasmic staining in
normal and neoplastic epithelial cells (representative examples are
shown in Fig. 6B). Compared to normal tissues, higher grades of
staining were generally found in tumor samples. Moderate to
marked labeling by anti-FGFR4 was apparent in tumors from
pancreas (in 41% of specimens), breast (46%), lung (31%), ovary
(41%), colon (90%), liver (33%), and thyroid (11%) (Table S1 and
ref. [23]). The widespread expression of FGFR4 in human HCC
was also previously confirmed by in situ hybridization [23].
Because a link between FGFR4 and HCC has already been
suggested we decided to further evaluate FGFR4 expression in 23
primary human liver tumors and 11 normal livers using
quantitative real-time polymerase chain reaction (qRT-PCR).
The expression of FGFR4 in each sample was normalized to the
expression of this gene in the first normal liver sample (N1). The
average level of FGFR4 expression was moderately increased in
liver tumors (1.22-60.05-fold) compared to normal livers (0.90-
60.04-fold), but the difference did not reach statistical significance
(p=0.23) when that population was considered as a whole
(Fig. 6C). However, FGFR4 expression was significantly higher
(more than 2-fold) in a subset of tumors (7/23; 30%). These results
illustrate that FGFR4 expression is deregulated in several types of
cancer. The increased expression of FGFR4 in a subset of liver
tumors suggests that it may represent an attractive target for the
treatment of liver cancer in a diagnostic-selected patient popula-
tion.
Discussion
In this study, we provide evidence that FGFR4 participates in
hepatocellular carcinoma and that treatment with an FGFR4
inactivating antibody can provide anti-tumor benefits. To evaluate
the participation of FGFR4 in liver tumorigenesis we used
genetically engineered mouse models. The exogenous expression
of FGF19 was shown to promote hepatocyte proliferation,
hepatocellular dysplasia, and the development of HCC in mice.
In addition, we and others have demonstrated that Klotho b is
required for the liver-specific activities of FGF19 [16,19,24].
Because KLB and FGFR4 are most highly expressed in liver, we
hypothesized that the deregulation of the FGFR4 pathway is
responsible for the FGF19-mediated liver tumorigenesis. To test
this hypothesis we bred FGF19-TG mice with FGFR4-KO mice.
Preneoplastic hepatocellular proliferation and hepatocellular
neoplasia were found only in FGF19-TG mice with an FGFR4-
WT background. The liver tumorigenesis was abrogated in the
FGFR4-KO mice. We further challenged the mice by adminis-
tering a potent hepatocarcinogen, diethylnitrosamine. Treatment
with DEN accelerated the development of HCC in FGF19-TG
mice with an FGFR4-WT background, whereas no evidence of
liver neoplasia was found in the FGFR4-KO mice. The clear
conclusion is that FGFR4 is required for FGF19-promoted liver
tumorigenesis.
Together these data suggest a link between FGFR4, liver
tumorigenesis, and liver cancer progression. Consequently,
FGFR4 is a potential therapeutic target and its inhibition may
provide a therapeutic benefit to liver cancer patients. To this end
we developed an anti-FGFR4 neutralizing antibody (LD1). LD1
binds to FGFR4 and inhibits ligand binding, pathway activation,
regulation of gene expression, cell proliferation, and colony
formation in vitro. The site at which LD1 binds to FGFR4 was
localized by evaluating the interaction of LD1 with FGFR4
constructs bearing point mutations at sites that are similar
between the FGFR4 orthologs but dissimilar in the FGFR1-3
orthologs; these amino acid residues in FGFR4 were substituted
with the amino acid residues present at the equivalent positions
in FGFR3. LD1 bound to wild type FGFR4 and most of the
mutant FGFR4 constructs with the exception of the G165A
mutant. The replacement of a glycine by an alanine at position
165 of FGFR4 nearly abolished LD1 binding. The exquisite
specificity of LD1 for FGFR4 combined with the high identity of
this region between FGFRs emphasizes the importance of this
residue for LD1 binding. Glycine 165 in FGFR4 corresponds to
alanine 171 in FGFR1. Interestingly, alanine 171 is the residue
at the closest approach in the FGFR1 dimer interface [25].
Across the axis of the dimer, the side chain of alanine 171 of one
receptor makes a hydrophobic contact with alanine 171 of the
adjacent receptor. The sequence conservation in this region of
the FGFRs is consistent with this region forming a receptor-
receptor interface [25]. Thus, the binding of LD1 to this
equivalent region of FGFR4 is likely disrupting receptor
dimerization. Ligand-induced receptor dimerization is essential
for the activation of FGFRs [26,27]. Therefore, inhibition of
FGFR4 dimerization is a potential mechanism of action for LD1.
A similar mechanism of action has already been described for
other therapeutic antibodies [28].
We showed that in vivo, LD1 acts on liver cancer xenograft
tumors by inhibiting the modulation of genes downstream from
FGFR4 and by blocking tumor growth. In addition, the
administration of LD1 inhibited the formation and development
of HCCs in FGF19-TG mice.
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tumorigenesis and cancer progression. In particular, our results
suggest that FGFR4 may play an important role in hepatocellular
carcinoma. Several lines of evidence support this hypothesis.
FGFR4 is the predominant FGFR isoform present in human
hepatocytes [15]. We have previously reported that liver tissue has
the highest FGFR4 and KLB transcript levels, and both of these
proteins are essential for ligand-stimulated activity by this signaling
complex [16]. Furthermore, ectopic expression of FGF19 (i.e.
FGFR4-specific ligand) in mice promotes hepatocyte proliferation,
hepatocellular dysplasia, and neoplasia [18] and FGF19-induced
hepatocyte proliferation has been reported to be uniquely
mediated by FGFR4 [24]. A recent report suggests that FGFR4
also contributes significantly to HCC progression by modulating
alpha-fetoprotein secretion, proliferation, and anti-apoptosis [17].
FGFR4 expression has also been shown to promote resistance to
chemotherapy [29]. It should be noted that one group has
reported a protective role, rather than an HCC promoting effect,
for FGFR4 in mice [30]. It is possible that contextual factors
including the identity and concentration of ligand, as well as the
levels of FGFRs and co-receptor expression might modulate the
role of FGFR4 in tumorigenesis. For example, we found FGFR4
Figure 6. FGFR4 expression is deregulated in cancer. A, Whisker-box plots show FGFR4 expression in human tumors and normal tissues as
determined by mRNA analysis of the BioExpress database. The center line indicates the median; the box represents the interquartile range between
the first and third quartiles. ‘‘Whiskers’’ extend from the interquartile to the positions of extreme values. B, FGFR4 immunostaining in samples of
breast (6100 magnification) and pancreatic (6100 magnification) adenocarcinomas, and hepatocellular carcinoma (6200 magnification and 6400
magnification). C, FGFR4 mRNA expression in a panel of human normal liver and liver tumors as determined by qRT-PCR. The value for each sample is
represented as fold expression relative to the level observed in sample N1.
doi:10.1371/journal.pone.0036713.g006
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tumors, suggesting that FGFR4 may represent an attractive target
for the treatment of liver cancer in a diagnostic-selected patient
population. Given the accumulating evidence for the participation
of FGFR4 in liver tumorigenesis and HCC progression, we believe
that a therapeutic intervention that includes an anti-FGFR4
neutralizing antibody is likely to be beneficial in the treatment of
liver cancer.
Materials and Methods
Ethics Statement
All animal studies were conducted in accordance with the Guide
for the Care and Use of Laboratory Animals, published by the
National Institutes of Health (NIH) (NIH Publication 8523,
revised 1985). The Institutional Animal Care and Use Committee
(IACUC) at Genentech reviewed and approved all animal
protocols. The approval IDs for this study are: 02–258, 04–
0161, 06–1387 A, 06–1581 I, 07–0978 B, and 07–0978 C.
In silico Expression Analysis
For expression analysis, box- and whisker-plots were generated
for FGFR4 with the normalized gene expression data extracted
from the BioExpress
TM database (Gene Logic, Gaithersburg,
MD). The distribution of FGFR4 expression in normal and cancer
tissues was evaluated using the signals associated with probe
204579_at.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were treated
for antigen retrieval using Trilogy (Cell Marque, Rocklin, CA) and
then incubated with 10 mg/mL anti-FGFR4 antibody (8G11;
Genentech, South San Francisco, CA). The immunostaining was
accomplished using a biotinylated secondary antibody, an ABC-
HRP reagent (Vector Laboratories, Burlingame, CA), and a
metal-enhanced DAB colorimetric peroxidase substrate (Thermo
Fisher Scientific, Rockford, IL).
Semi-quantitative RT-PCR
Total RNA was extracted using the RNeasy kit (Qiagen,
Valencia, CA). Specific primers and fluorogenic probes were used
to amplify and quantitate gene expression [31]. The gene-specific
signals were normalized to the RPL19 housekeeping gene. All
TaqMan qRT-PCR reagents were purchased from Applied
Biosystems (Foster City, CA). A minimum of a triplicate set of
data was analyzed for each condition. Data are presented as the
mean 6 SEM.
Immunoprecipitation and Immunoblotting
Lysates of cultured cells or frozen tissues were prepared with
RIPA lysis buffer (Millipore, Billerica, MA) supplemented with
Complete EDTA-free protease inhibitor cocktail (Roche, India-
napolis, IN), phosphatase inhibitor cocktails 1 and 2 (Sigma-
Aldrich, St. Louis, MO), 2 mM sodium fluoride, and 2 mM
sodium orthovanadate. Equal amounts of protein, as determined
by BCA assay (Thermo Fisher Scientific) were analyzed by
immunoblot analysis using antibodies against FGFR4 (8G11;
Genentech), FGFR3 (Santa Cruz Biotechnology, Santa Cruz, CA),
FGFR2 (GeneTex, Irvine, CA) and FGFR1 (Santa Cruz
Biotechnology). For the human liver lysates, the immunoblot
analysis was preceded by the immunoprecipitation of FGFR4 as
described previously [16].
Generation of FGFR4 Monoclonal Antibodies
FGFR4 null mutant (i.e. FGFR4-KO) mice were immunized
with recombinant human and mouse FGFR4-Fc chimeric proteins
(Genentech). Spleens were harvested after 8 weeks and hybrid-
omas were generated. Cultured supernatants were collected and
screened by solid phase antibody binding assay against the
immunogens. Positive cell lines were further screened using solid
phase receptor binding assay for their efficacy at inhibiting FGF1
and FGF19 binding to human and mouse FGFR4. The LD1-
producing hybridoma was subcloned twice to insure monoclon-
ality.
Molecular Cloning of LD1
Total RNA was extracted from hybridoma cells producing
muLD1 using the RNeasy Mini kit (Qiagen). The variable light
and variable heavy domains were amplified using reverse
transcription-PCR (RT-PCR). The forward primers were specific
for the NH2-terminal amino acid sequence of the variable light
and variable heavy regions. Respectively, the light chain and
heavy chain reverse primers were designed to anneal to regions in
the constant light and constant heavy domain 1 that are highly
conserved across species. Amplified variable light chain was cloned
into a mammalian expression vector containing the human k
constant domain. Amplified variable heavy chain was inserted into
a mammalian expression vector encoding the full-length human
IgG1 constant domain. The chimeric antibody was transiently
expressed as previously described [16].
Solid Phase Antibody Binding Assay
Maxisorp 96 well plates were coated overnight at 4uC with
50 mLo f2 mg/mL anti-human immunoglobulin Fc fragment-
specific (Jackson ImmunoResearch Laboratories, West Grove, PA)
or anti-FLAG antibody (Sigma-Aldrich). The non-specific binding
sites were saturated with 200 mL PBS/3% bovine serum albumin
(BSA) for 1 hour and FGFRs-IgG (Genentech and R&D Systems,
Minneapolis, MN) or FLAG tagged-FGFR4 (FGFR4DTM-FLAG)
were incubated in PBS/0.3% BSA for 1 hour. The plates were
washed and incubated for 1 hour with anti-FGFR4 antibodies in
PBS/0.3% BSA. The bound antibodies were detected using an
HRP-conjugated anti-IgG (Jackson ImmunoResearch Laborato-
ries) and the TMB peroxidase colorigenic substrate (KPL,
Gaithersburg, MD).
Flow Cytometry Analysis
Cells for flow cytometry analysis were resuspended with PBS
containing 5 mM EDTA and washed with PBS containing 2%
heat-inactivated fetal bovine serum (FBS). All subsequent steps
were carried out on ice. Cells (1610
6) were incubated with a
primary antibody (LD1 or isotype control) for 30 minutes, followed
by incubation with phycoerythrin (PE)-conjugated anti-human
IgG antibody (Jackson ImmunoResearch). Cells were analyzed
with a FACScan flow cytometer (BD Biosciences, San Jose, CA).
DNA Constructs
The human FGFR4 (hFGFR4) cDNA was cloned as described
previously [16]. The extracellular domain of FGFR4 was also
subcloned into the expression vector pCMV-Tag4A (Stratagene,
La Jolla, CA) to obtain a secreted form of FGFR4 with a FLAG
tag at the C-terminal end (FGFR4DTM-Flag). Single nucleotide
mutations were introduced in the FGFR4DTM-Flag constructs
using the QuikChange XL Site-Directed Mutagenesis Kit
(Stratagene). We also generated a human FGFR4-FGFR1
chimeric construct (hFGFR4/R1) that contained the extracellular
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36713and the transmembrane domains of human FGFR4 fused to the
cytoplasmic domain of human FGFR1. The amino acid sequence
joining FGFR4 (bold) to FGFR1 (plain) is ???AVLLLLA-
GLYRGKMKSG???. The hFGFR4 cDNA or hFGFR4/R1
cDNA was ligated into the pQCXIP retroviral bicistronic
expression vector (Clontech Laboratories, Mountain View, CA).
FGFR4DTM-Flag-conditioned Medium
HEK293 cells were transfected with the wild type or mutant
FGFR4DTM-Flag constructs or the corresponding empty vector
and maintained in serum free PS25 medium for 72 to 96 hours.
The resulting media were filtered, supplemented with HEPES
pH 7.2 (final concentration 40 mM), and protease inhibitors and
stored at 4uC until used.
Cell Culture and Stable Cell Lines
HEK293, HEPG2, and HEP3B cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA) and
maintained in F-12:DMEM mix (50:50) supplemented with 10%
FBS and 2 mM L-glutamine. HUH7 and PLC/PRF/5 cells were
cultured in DMEM high glucose, 10% FBS. JHH4, JHH5, and
JHH7 cells were purchased from the Japanese Cancer Research
Resources Bank (Tokyo, Japan) and maintained in Williams
Medium E supplemented with 10% FBS and 2 mM L-glutamine.
SNU449 cells were obtained from ATCC and maintained in
RPMI 1640 containing 10% FBS and 2 mM L-glutamine. BaF3
cells were maintained in RPMI 1640 (Life Technologies, Carlsbad,
CA) supplemented with 10% FBS, 1 ng/mL IL-3, and 2 mM L-
glutamine. L6 cells were obtained from ATCC and maintained in
DMEM high glucose supplemented with 10% FBS.
Cultures of BaF3 and L6 cells were infected with the empty,
hFGFR4, or hFGFR4/R1 retroviral expression vectors according
to the manufacturer’s recommendations and selected in media
containing 2.5 mg/mL puromycin (Life Technologies) for 10 to 12
days. From the selected pools, the top five percent of highest
expressing cells was isolated by Fluorescence Activated Cell
Sorting (FACS) using an anti-FGFR4 antibody (8G11; Genen-
tech). The resulting pools of cells expressing high levels of FGFR4,
high levels of FGFR4/R1, and the control cells stably transfected
with an empty vector were maintained in complete medium
containing 2.5 mg/mL puromycin.
Mitogenic Assays
BaF3/control, BaF3/FGFR4, and BaF3/FGFR4/R1 cells were
washed twice and seeded in 96-well plates (22,500 cells/well) in
RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine,
and 2 mg/mL heparin. FGFs were added to each well and the cells
were incubated at 37uC for 72 hours. The relative cell density was
measured using CellTiter-Glo (Promega, Madison, WI) according
to the manufacturer’s recommendations.
Anti-FGFR4 Antibody Inhibition of FGF Pathway
Activation
Cells were serum starved for 24 hours in the absence or
presence of LD1 or an isotype control antibody. They were then
stimulated with 5 ng/mL FGF1 (FGF acidic, R&D Systems) and
10 mg/mL heparin for 5 minutes. The cells were lysed with RIPA
lysis buffer (Millipore) supplemented with Complete EDTA-free
protease inhibitor cocktail (Roche), phosphatase inhibitor cocktails
1 and 2 (Sigma-Aldrich), 2 mM sodium fluoride, and 2 mM
sodium orthovanadate. Equal amounts of protein were analyzed
by immunoblot using antibodies against phospho-ERK1/2,
phospho-FRS2, ERK1/2 (Cell Signaling Technology, Danvers,
MA), and FRS2 (Millipore).
Clonogenic Assay
HUH7 (5,000 cells/well), PLC/PRF/5 (2,000 cells/well), JHH5
(500 cells/well), or JHH5/hFGFR4 shRNA (500 cells/well) cells
were seeded in 2 mL medium/well in 6 well plates, in triplicate.
Three hours after seeding, the HUH7 and PLC/PRF/5 cells were
treated without or with anti-FGFR4 antibody (chLD1; Genen-
tech). Antibody was replaced twice weekly for the duration of the
experiment (14 days). For the JHH5 and JHH5/hFGFR4 shRNA
cells, treatment without or with 2 mg/mL doxycycline was initiated
3 hours after seeding, and replaced three times weekly for the
duration of the experiment. Cells were washed with PBS and
stained with 0.5% crystal violet solution. Colonies were counted
using MetaMorph software (Molecular Devices, Sunnyvale, CA).
In vivo Experiments
Female FVB mice that were 5 to 6 weeks old were obtained
from Charles River Laboratories International (Wilmington, MA).
Mice were given intraperitoneal (IP) injections (10 mg/kg) of a
control or an anti-FGFR4 (chLD1) antibody. Forty-eight hours
later, the mice received vehicle (PBS) or 1 mg/kg FGF19
intravenously (IV); the mice were provided standard feed and
water ad libitum until 12 hours before injection with FGF19, at
which time feed was removed. After 30 minutes, mice from all
groups were necropsied and tissue samples were collected, frozen
in liquid nitrogen, and stored at 270uC. Total RNA from frozen
tissue samples was prepared using the RNeasy kit (Qiagen).
Groups of 3 to 5 animals were analyzed for each condition. Data
are presented as the mean 6 SEM and were analyzed by the
Student’s t-test.
For xenograft experiments, 6- to 8-week-old nu/nu female mice
(Charles River Laboratories International) were inoculated sub-
cutaneously with 5610
6 cells (200 mL/mouse) and Matrigel (BD
Biosciences). Mice bearing tumors of equivalent volumes
(,150 mm
3) were randomized into groups (n=10) and treated
IP once weekly in the initial experiment and twice weekly in the
repeat experiment. Tumors were measured with an electronic
caliper (Fowler Sylvac Ultra-Cal Mark III; Fred V. Fowler
Company, Newton, MA) and average tumor volume was
calculated using the formula: (W
26L)/2 where W and L are the
smaller diameter and larger diameter, respectively. Data are
presented as the mean tumor volume 6 SEM and were analyzed
by the Student’s t-test.
The FGF19 transgenic mice were produced as described
previously [32]. The FGFR4-KO animals were constructed as
reported previously [33] and provided by W. L. McKeehan
(University of Texas Southwestern Medical Center, Dallas, TX).
Mice that both overexpressed FGF19 and lacked the FGFR4
receptor (FGF19-TG:FGFR4-KO) were fabricated by crossing
young adult FGF19-TG males with young adult FGFR4-KO
females. The presence of both gene engineering events was
confirmed at weaning by PCR on tail DNA.
Supporting Information
Figure S1 LD1 binds to FGFR4. A, LD1 binds to HEK293
cells transiently transfected with a human (hFGFR4) expression
construct, but not to HEK293 cells transfected with control empty
vector. B, LD1 binds to HEK293 cells transiently transfected with
an hFGFR4 expression construct, but not to HEK293 cells
transfected with hFGFR1, hFGFR2,o rhFGFR3 expression
constructs. C, LD1 binds to JHH5 cells endogenously expressing
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36713FGFR4. JHH5 cells stably transfected with FGFR4 shRNA exhibit
diminished LD1 binding upon treatment with 2 mg/mL doxycy-
cline for 48 and 96 hours.
(TIF)
Figure S2 Expression of FGFRs in liver cancer cell lines.
A, FGFR1-FGFR4 mRNA expression in a panel of liver tumor cell
lines as determined by qRT-PCR. The values are represented as
fold expression relative to the FGFR1 levels in the JHH4 cell line.
B, FGFR4 protein expression in the same panel of cell lines as in
Fig. S2A as determined by Western blot.
(TIF)
Figure S3 LD1 inhibits FGFR4 biological activities in
HUH7 cells. LD1 inhibits the FGFR4-regulated CYP7A1
repression in HUH7 cells. CYP7A1 levels are represented as fold
expression relative to the level in untreated cells.
(TIF)
Figure S4 In vivo efficacy of LD1. LD1 (30 mg/kg; twice
weekly) inhibits HUH7 xenograft tumor growth in vivo. The anti-
tumor efficacy of LD1 was evaluated in a biweekly modality.
(TIF)
Table S1 FGFR4 expression in normal and cancer
tissues. Prevalence of FGFR4 expression in normal and cancer
tissues as determined by histopathological evaluation of FGFR4
immunostaining.
(TIF)
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